Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Depreciation & Amortization (CF): 2016-2024

Historic Depreciation & Amortization (CF) for Krystal Biotech (KRYS) over the last 9 years, with Dec 2024 value amounting to $6.0 million.

  • Krystal Biotech's Depreciation & Amortization (CF) rose 7.69% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 8.73%. This contributed to the annual value of $6.0 million for FY2024, which is 19.83% up from last year.
  • According to the latest figures from FY2024, Krystal Biotech's Depreciation & Amortization (CF) is $6.0 million, which was up 19.83% from $5.0 million recorded in FY2023.
  • Krystal Biotech's Depreciation & Amortization (CF)'s 5-year high stood at $6.0 million during FY2024, with a 5-year trough of $1.9 million in FY2020.
  • Its 3-year average for Depreciation & Amortization (CF) is $5.0 million, with a median of $5.0 million in 2023.
  • Data for Krystal Biotech's Depreciation & Amortization (CF) shows a peak YoY spiked of 69.82% (in 2020) over the last 5 years.
  • Over the past 5 years, Krystal Biotech's Depreciation & Amortization (CF) (Yearly) stood at $1.9 million in 2020, then soared by 49.59% to $2.8 million in 2021, then soared by 46.44% to $4.1 million in 2022, then increased by 23.48% to $5.0 million in 2023, then rose by 19.83% to $6.0 million in 2024.